Intravenous Immunoglobulin Market Size, Share, Regional Demand and Geographical Forecast till 2030

The Intravenous Immunoglobulin Market was valued at US$ 11,206.54 million in 2021 and is expected to reach value of US$ 18,672.55 million by 2028; it is estimated to grow at a CAGR of 7.6% from 2022 to 2028.

Rising prevalence of immunodeficiency diseases and the increasing geriatric population fuel the overall market growth.

According to the National Institute of Allergy and Infectious Diseases (NIAID), over 200 different types of primary immune deficiency diseases (PIDDs) affect about 500,000 people in the US. The rare genetic diseases can be chronic, weak, and expensive to treat. Immune Thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by abnormally low levels of platelets, a situation referred to as thrombocytopenia.

Get Exclusive Sample PDF @: https://www.premiummarketinsights.com/sample/TIP00010546?utm_source=OpenPr&utm_medium=10640

Analysis of the Top Market Players:

1. Takeda Pharmaceutical Company Limited
2. Grifols, S.A.
3. Pfizer Inc.
4. ADMA Biologics Inc.
5. Bio Products Laboratory Ltd.
6. Shanghai RAAS
7. Octapharma AG
8. Kedrion S.p.A
9. CSL Behring (CSL Limited)
10. Prothya Biosolutions B.V.

In this report, the market has been segmented on the basis of:

Type (IgG, IgM, IgA, IgE, and IgD)

Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre syn)

According to the Rare Diseases Organization, around 200,000 ITP cases are recorded worldwide annually. Further, according to the United Nations Population Division, World Population Prospects 2019, Asian and European countries have some of the world's oldest populations aged 65 and over. Japan being at the top with 28%, followed by Italy at 23%. Furthermore, Finland, Portugal, and Greece are among the top five countries with aged population under 22%. Many of the patients treated with IVIG are above the age of 60 years. With aging, the ability to produce T-cells to fight diseases gets significantly reduced. Thus, an older person's body is easily prone to several infections and diseases, which increases the demand for immune therapies that involve the use of IVIg. Thus, the rise in immunodeficiency diseases and the increasing geriatric population globally bolster the growth of the intravenous immunoglobulin market.

Access full Report Description, TOC, Table of Figure, Chart, etc. @: https://www.premiummarketinsights.com/reports-tip/intravenous-immunoglobulin-market

Intravenous Immunoglobulin Market: Segmental Overview

Based on the type, the intravenous immunoglobulin market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG type immunoglobulin segment will hold the largest market share in 2021. However, the handheld segment is anticipated to register the highest CAGR during the forecast period owing to its wide application of IgG in treating several disorders. Based on application, the intravenous immunoglobulin market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, inflammatory myopathies, specific antibody deficiency, Guillain-Barre syndrome, and others. In 2021, the immunodeficiency diseases segment will likely hold the market's largest share. Moreover, the same segment is expected to witness growth in its demand at the fastest CAGR from 2022 to 2028 due to the rising prevalence of immunodeficiency diseases and increasing FDA approvals for IVIg products to treat immunodeficiency.

Order a copy of this research report at @: https://www.premiummarketinsights.com/buy/TIP00010546?utm_source=OpenPr&utm_medium=10640

Contact Us:
If you have any queries about this report or if you would like further information, please
Contact Person: Ankit Mathur
Phone: +1-646-491-9876
Email: sales@premiummarketinsights.com

About Us:
Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost-effective research reports and solutions from various publishers.
The market research industry has changed in last decade. As corporate focus has shifted to niche markets and emerging countries, a number of publishers have stepped in to fulfil these information needs. We have experienced and trained staff that helps you navigate different options and lets you choose best research solution at most effective cost.
Premium Market Insights has an extensive coverage of industry reports, company reports and country reports across all industries. In case your research needs are not met by syndicated reports offered by leading publishers, we can help you by offering a customized research solution by liaising with different research agencies saving your valuable time and money.
We provide best in class customer service and our customer support team is always available to help you on your research queries. Our commitment to customer service is best exemplified by free analyst support that we offer to our clients which sets us apart from any other provider. We also offer enterprise subscriptions which provide significant cost savings to our clients.

This release was published on openPR.